Online tool encourages families to bone up on genetics

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 12
Volume 17
Issue 12

Ohio State University’s Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute have developed a free, online assessment tool that allows individuals to enter their family medical history, and determine their risk for both cancer and coronary heart disease.

Ohio State University’s Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute have developed a free, online assessment tool that allows individuals to enter their family medical history, and determine their risk for both cancer and coronary heart disease.

Called Family HealthLink, the tool was created by the Clinical Cancer Genetics and Medical Genetics Programs. The survey takes approximately 15 minutes to complete and provides a printable risk assessment that can be used for discussion with a physician or genetic counselor.

“It is important that families take the time to discuss their health in order to better understand their risk for cancer and coronary heart disease and improve screening and prevention methods,” said Kevin Sweet, genetic counselor and director of the Family HealthLink project.

To access Family HealthLink, go to familyhealthlink.osumc.edu or call 1-888-329-1654 to reach the genetics programs by phone.

Articles in this issue
Radiology resident compiles staging database
Study links the risk of ALCL to silicone breast implants
CyBorD combo supports stem cell collection in newly diagnosed multiple myeloma
Clara Bloomfield: Buck conventional wisdom always
New breast cancer program reduces time to treatment
PET/CT for prostate ca influences staging, treatment strategy
Racially-based disparities in ca on the rise, not due to smoking
ProStrakan offers patch to prevent nausea and vomiting
Online tool encourages families to bone up on genetics
Bevacizumab plus copper radiotracer shines as imaging probe
Coverting unresectable to resectable: Data still limited
AACR commits to Love/Avon Army of Women
Voters pass end-of-life measure in Washington state
Brachytherapy improves treatment in augmented women
Marathon effort to support cancer care
Recent Videos
Treatment with lorlatinib did not increase cardiovascular events among patients with ALK-positive non–small cell lung cancer in the CROWN trial.
Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.
At 5 years, 60% of patients who received lorlatinib in the phase 3 CROWN study achieved progression-free survival.
Joseph C. Landolfi, DO, CPE, and Michelle Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Leadership of a new cancer center as part of JFK University Medical Center discuss how they can support frontline clinicians.
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
Related Content
67 Confocal Laser Scanning Microscopy (CLSM) for Intraoperative Histopathological Margin Assessment in Breast Conservation Surgery

67 Confocal Laser Scanning Microscopy (CLSM) for Intraoperative Histopathological Margin Assessment in Breast Conservation Surgery

Ken Weixing Ho;Nicholas Holford;Rathi Ramakrishnan;Patriek Jurrius;Sarah Pinder;Arnie Purushotham;Daniel Leff
May 11th 2025
Article
Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
May 5th 2025
Podcast

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

68 Upper Extremity Disability Assessment Following Breast Cancer Surgery Using QuickDASH in an Ethnic Minority Population

68 Upper Extremity Disability Assessment Following Breast Cancer Surgery Using QuickDASH in an Ethnic Minority Population

Arianna Cavalli;Susan Laura Jao;Skylar Harbour;Melissa Rony;Sheldon Feldman;Maureen McEvoy
May 10th 2025
Article
Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer

Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer

Manojkumar Bupathi, MD, MS;Manojkumar Bupathi, MD, MS
May 1st 2025
Podcast

Oncology Decoded hosts discuss adjuvant therapy in kidney cancer, including research, treatment strategies, and management of recurrence.

"Our preliminary results showed that the efficacy of fruquintinib combined with capecitabine is promising with well tolerance as maintenance therapy in RAS/BRAF wild-type mCRC,” according to lead study author, Kai Ou.

Fruquintinib Combo Shows Early Activity in RAS/BRAF+ Metastatic CRC

Courtney Flaherty
May 9th 2025
Article

At the time of analysis, the median progression-free survival was not reached with fruquintinib plus capecitabine in a phase 1/2 trial.

70 Malignancy Upgrade Rates of Discordant Breast Lesions

70 Malignancy Upgrade Rates of Discordant Breast Lesions

Jacquelyn Dillon;Carolyn Vanek;Jeanne Wu;Grace Van Hyfte;Victoria Collins;Christine Chen;Elisa Port;Jennifer L. Marti
May 9th 2025
Article